Targeted Therapies in Low-Grade Serous Ovarian Cancers

Opinion Statement Low grade serous carcinoma of the ovary has been delineated as a separate entity from its counterpart high grade serous carcinoma of the ovary. Molecular profiling has helped to further characterize this disease process and has led to new and exciting treatment options. Surgery has...

Full description

Saved in:
Bibliographic Details
Published in:Current treatment options in oncology 2024-07, Vol.25 (7), p.854-868
Main Authors: Gonzalez, Anna, Nagel, Christa I., Haight, Paulina J.
Format: Article
Language:English
Subjects:
Biomarkers, Tumor
Chemotherapy
Clinical trials
Clinical Trials as Topic
Combined Modality Therapy - adverse effects
Cystadenocarcinoma, Serous - drug therapy
Cystadenocarcinoma, Serous - pathology
Cystadenocarcinoma, Serous - therapy
Disease Management
Female
Humans
Medicine
Medicine & Public Health
Molecular Targeted Therapy - methods
Neoplasm Grading
Neoplasm Staging
Oncology
Ovarian cancer
Ovarian carcinoma
Ovarian Neoplasms - drug therapy
Ovarian Neoplasms - pathology
Topical Collection on Gynecologic Cancers
Treatment Outcome
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Opinion Statement Low grade serous carcinoma of the ovary has been delineated as a separate entity from its counterpart high grade serous carcinoma of the ovary. Molecular profiling has helped to further characterize this disease process and has led to new and exciting treatment options. Surgery has always been a cornerstone of management both in primary and recurrent disease settings. Chemotherapy has been a long-standing backbone of adjuvant treatment, but its efficacy continues to be questioned. Hormonal therapy for upfront and recurrent disease is an effective treatment option with a high response rate and minimal side effects. Newer therapies including MEK, CDK 4/6, and PI3KCA inhibitors have emerged as exciting options for recurrent disease. Ongoing clinical trials will hopefully lead to additional therapeutic opportunities based on novel biomarkers in this disease.
ISSN:1527-2729
1534-6277
1534-6277
1534-5277
DOI:10.1007/s11864-024-01205-4